Mental health tops in overall spending at $201B

A new report from Health Affairs examined federal data on healthcare spending to rank the 10 costliest conditions in the U.S. Tops on the list: Mental health accounted for $201 billion in 2013. Heart conditions came in next at $147 billion, with trauma rounding out the top three at $143 billion.

The study, written by Charles Roehrig of the Center for Sustainable Health Spending at Altarum Institute in Ann Arbor, Michigan, updated a 2009 report that estimated health expenditures by medical condition through 2013.

Spending rates on heart problems and strokes grew at a rate lower than overall spending, which the report attributes to decreased smoking and other improved lifestyle changes. But the positives in those areas of care partly attribute to the growth in spending on mental disorders.

“A look ahead suggests that reductions in deaths from heart conditions and cerebrovascular disease are likely to drive spending on mental disorders even higher, as more people survive to older ages—when mental disorders, such as dementia, become more prevalent,” Roehrig wrote.

More than 40 percent of the $201 billion in mental health spending went to institutionalized individuals, a consideration the report claims other studies frequently overlook.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.